文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

萝卜硫素可能通过激活Nrf2/HO-1通路减轻复苏后肺细胞焦亡

SULFORAPHANE ALLEVIATES POSTRESUSCITATION LUNG PYROPTOSIS POSSIBLY VIA ACTIVATING THE NRF2/HO-1 PATHWAY.
PubMed 文献 · Shock · 2023-07-12
一句话结论猪心脏骤停复苏模型中,复苏后静脉输注萝卜硫素2 mg/kg可减轻复苏后肺损伤与肺细胞焦亡,其作用可能与激活Nrf2/HO-1通路有关。

研究在24头猪中建立10分钟心脏骤停后6分钟心肺复苏模型,随机分为假手术组(n=6)、心肺复苏组(n=9)和心肺复苏+萝卜硫素组(n=9)。自主循环恢复后,萝卜硫素组以2 mg/kg稀释于20 mL生理盐水静脉输注5分钟。复苏后2、4小时,萝卜硫素组的血管外肺水指数和肺血管通透性指数较心肺复苏组显著改善;复苏后24小时肺组织病理损伤评分降低、氧化失衡改善、焦亡相关促炎细胞因子(IL-1β、IL-18)和焦亡相关蛋白(NOD样受体热蛋白结构域3、cleaved caspase 1、GSDMD、GSDMD N端)下调,Nrf2/HO-1通路激活。结论认为萝卜硫素通过减轻肺细胞焦亡产生复苏后肺保护作用,机制可能为激活Nrf2/HO-1通路。

要点

  • 猪心脏骤停复苏模型中,复苏后静脉输注萝卜硫素2 mg/kg(稀释于20 mL生理盐水,输注5分钟)可减轻复苏后肺损伤。
  • 复苏后2小时和4小时,萝卜硫素组的血管外肺水指数和肺血管通透性指数较心肺复苏组显著改善。
  • 复苏后24小时,萝卜硫素组肺组织病理损伤评分降低,超氧化物歧化酶和丙二醛反映的氧化失衡改善。
  • 萝卜硫素组肺组织IL-1β、IL-18及NOD样受体热蛋白结构域3、cleaved caspase 1、GSDMD、GSDMD N端表达下调,Nrf2/HO-1通路激活。
  • 心肺复苏期间自主循环恢复的猪数:心肺复苏组6头,心肺复苏+萝卜硫素组7头。

适用人群与场景

  • 猪心脏骤停复苏模型:10分钟心脏骤停后行6分钟心肺复苏,自主循环恢复后观察4小时、24小时取肺组织。

处置流程与药物剂量

  • 自主循环恢复后,将萝卜硫素2 mg/kg稀释于20 mL生理盐水,静脉输注,输注时间5分钟。

研究设计与关键结果

  • 研究类型为动物实验,24头猪随机分为假手术组(n=6)、心肺复苏组(n=9)、心肺复苏+萝卜硫素组(n=9)。
  • 心肺复苏期间自主循环恢复:心肺复苏组6头,心肺复苏+萝卜硫素组7头。
  • 复苏后2小时和4小时,血管外肺水指数和肺血管通透性指数在萝卜硫素组与心肺复苏组之间差异显著,萝卜硫素组均优于心肺复苏组。
  • 复苏后24小时,与心肺复苏组相比,萝卜硫素组肺损伤评分显著降低,超氧化物歧化酶和丙二醛反映的氧化失衡改善。
  • 复苏后24小时,与心肺复苏组相比,萝卜硫素组IL-1β、IL-18含量降低,NOD样受体热蛋白结构域3、cleaved caspase 1、GSDMD、GSDMD N端表达下调,Nrf2/HO-1通路激活。

证据类型、等级与局限

  • 证据类型:动物实验(猪心脏骤停复苏模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,萝卜硫素通过减轻肺细胞焦亡、可能经由激活Nrf2/HO-1通路,在猪中产生有效的复苏后肺保护作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Introduction: Sulforaphane (SFN), known as the activator of the nuclear factor E2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway, has been proven to protect the lung against various pathological stimuli. The present study aimed to investigate the effect of SFN on lung injury induced by systemic ischemia reperfusion after cardiac arrest and resuscitation. Methods: After animal preparation, 24 pigs were randomly divided into sham group (n = 6), cardiopulmonary resuscitation group (CPR, n = 9), or CPR + SFN group (n = 9). The experimental model was then established by 10 min of cardiac arrest followed by 6 min of CPR. Once spontaneous circulation was achieved, a dose of 2 mg/kg of SFN diluted in 20 mL of saline was intravenously infused with a duration of 5 min. During 4 h of observation after resuscitation, extravascular lung water index (ELWI), pulmonary vascular permeability index (PVPI), and oxygenation index were regularly evaluated. At 24 h after resuscitation, lung tissues were harvested to evaluate the score of lung histopathological injury, the activity of superoxide dismutase, the contents of malondialdehyde, IL-1β, and IL-18, and the expression levels of NOD-like receptor pyrin domain 3, cleaved caspase 1, gasdermin D (GSDMD), GSDMD N-terminal, Nrf2, and HO-1. Results: During CPR, spontaneous circulation was achieved in six and seven pigs in the CPR and CPR + SFN groups, respectively. After resuscitation, the indicators of lung injury (ELWI, PVPI, and oxygenation index) were all better in the CPR + SFN group than in the CPR group, in which the differences in ELWI and PVPI at 2, and 4 h after resuscitation were significant between the two groups. In addition, SFN significantly reduced lung injury score, improved oxidative imbalance (superoxide dismutase, malondialdehyde), decreased pyroptosis-related proinflammatory cytokines (IL-1β, IL-18), downregulated pyroptosis-related proteins (NOD-like receptor pyrin domain 3, cleaved caspase 1, GSDMD, GSDMD N-terminal), and activated the Nrf2/HO-1 pathway when compared with the CPR group. Conclusion: SFN produced effective postresuscitation lung protection through alleviating lung pyroptosis possibly via activating the Nrf2/HO-1 pathway in pigs.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Li Y, Yang M, Xie L, et al. SULFORAPHANE ALLEVIATES POSTRESUSCITATION LUNG PYROPTOSIS POSSIBLY VIA ACTIVATING THE NRF2/HO-1 PATHWAY. Shock. 2023. PMID: 37548635. doi:10.1097/SHK.0000000000002180

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。